Tue, Apr 26|
Pfizer COVID-19 Oral Antiviral
Learn about the Pfizer antiviral nirmatrelvir/ritonavir combination sold under the brand name Paxlovid. Speakers are Shoaib Khan, MD, Field Medical Director, North American Medical Affairs, Pfizer; and Tracy R. Wilson, DNP, MSN.Ed., RN, FNP-C, Field Medical Director, Southwest Region, Pfizer.
Time & Location
Apr 26, 2022, 6:00 PM – 7:00 PM
About the event
Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of the nirmatrelvir/ritonavir combination sold under the brand name Paxlovid.
Attendees may have to download WebEx to view the presentation.
Information from Pfizer does not constitute endorsement or recommendation by MCMS.